Literature DB >> 28003718

Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.

Mitali M Rath1, Manas K Panigrahi2, Kaumudee Pattnaik3, Pallavi Bhuyan3, Sanjib K Kar4, Bijay Misra4, Debasis Misra4, Chudamani Meher5, Omprakash Agrawal5, Jayshree Rath3, Shivaram P Singh4.   

Abstract

BACKGROUND: Although liver biopsy remains the gold standard for the diagnosis of non-alcoholic fatty liver disease [NAFLD], many non-invasive markers of liver fibrosis have recently been proposed and assessed as surrogates of liver biopsy. AIMS AND
OBJECTIVE: To evaluate the degree of liver fibrosis by different non-invasive fibrosis scoring systems and to compare each non-invasive fibrosis scoring system with histological fibrosis stage.
MATERIALS AND METHODS: The study population consists of consecutive patients with biopsy proven NAFLD. Complete medical history was taken and physical examination was done in all patients along with appropriate biochemical evaluations. NAFLD fibrosis score, BARD score, BAAT score and APRI score were calculated and each score was compared with histological fibrosis staging.
RESULTS: The study population consisted of 60 patients having mean age 39.73 years (SD 9.62, range 17-63 years) including 51 (85%) males and 9 (15%) females. On histology fibrosis was present in 68.3% (41/60) patients. Out of 60 patients 41 had fibrosis and among them 17, 22, 2 patients had grade 1, 2, 3 fibrosis respectively and no one had grade 4 fibrosis. 61.67% (37/60) had definite NASH. Comparing the fibrosis of histology with the noninvasive scoring systems, the sensitivity and specificity of NAFLD fibrosis score were 5.56% and 100% respectively. BARD score had 45.83% sensitivity and 80.55% specificity. The sensitivities of BAAT score and APRI score were 0% and 29.16% respectively and the specificities were 100% and 97.22% respectively.
CONCLUSION: The noninvasive scoring systems like NFS, BARD, BAAT, and APRI are not sensitive enough to detect fibrosis but highly specific to include fibrosis if scores are more than cut-off values in our cohort, however they cannot replace liver biopsy. Newer more efficient non-invasive scoring systems have to be devised for the Indian NAFLD population.

Entities:  

Keywords:  ALT, alanine aminotransferase; APRI; APRI, aspartate aminotransferase (AST)-to-platelet ratio index; AST, aspartate aminotransferase; BAAT; BARD; BMI, body mass index; DM, diabetes mellitus; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD fibrosis score; NASH, non-alcoholic steatohepatitis; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; SGOT, serum glutamic oxaloacetic transaminases; SGPT, serum glutamic pyruvate transaminases; TG, triglyceride; TPC, total platelet count; fibrosis; nonalcoholic fatty liver disease (NAFLD)

Year:  2016        PMID: 28003718      PMCID: PMC5157877          DOI: 10.1016/j.jceh.2016.08.006

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  29 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Authors:  Elisabetta Bugianesi; Nicola Leone; Ester Vanni; Giulio Marchesini; Franco Brunello; Patrizia Carucci; Alessandro Musso; Paolo De Paolis; Lorenzo Capussotti; Mauro Salizzoni; Mario Rizzetto
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

3.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.

Authors:  Stephen H Caldwell; Deborah M Crespo
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083

4.  Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.

Authors:  Shivakumar Chitturi; Geoffrey C Farrell; Etsuko Hashimoto; Toshiji Saibara; George K K Lau; José D Sollano
Journal:  J Gastroenterol Hepatol       Date:  2007-06       Impact factor: 4.029

5.  Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians.

Authors:  Kaushal Madan; Yogesh Batra; S Datta Gupta; Bal Chander; K D Anand Rajan; M S Tewatia; S K Panda; S K Acharya
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.

Authors:  Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

7.  Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.

Authors:  Christophe Cassinotto; Jérome Boursier; Victor de Lédinghen; Jérome Lebigot; Bruno Lapuyade; Paul Cales; Jean-Baptiste Hiriart; Sophie Michalak; Brigitte Le Bail; Victoire Cartier; Amaury Mouries; Frédéric Oberti; Isabelle Fouchard-Hubert; Julien Vergniol; Christophe Aubé
Journal:  Hepatology       Date:  2016-01-22       Impact factor: 17.425

8.  Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis.

Authors:  A L Williams; J H Hoofnagle
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

9.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

10.  Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.

Authors:  V Mohan; S Farooq; M Deepa; R Ravikumar; C S Pitchumoni
Journal:  Diabetes Res Clin Pract       Date:  2009-01-24       Impact factor: 5.602

View more
  6 in total

Review 1.  Contemporary strategies to assess and manage liver donor steatosis: a review.

Authors:  Christine Tien; Daphne Remulla; Yong Kwon; Juliet Emamaullee
Journal:  Curr Opin Organ Transplant       Date:  2021-10-01       Impact factor: 2.269

2.  Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography.

Authors:  Constanze Bardach; Leonie Morski; Katharina Mascherbauer; Carolina Donà; Matthias Koschutnik; Kseniya Halavina; Christian Nitsche; Dietrich Beitzke; Christian Loewe; Elisabeth Waldmann; Michael Trauner; Julia Mascherbauer; Christian Hengstenberg; Andreas Kammerlander
Journal:  J Clin Med       Date:  2022-05-19       Impact factor: 4.964

3.  A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis.

Authors:  Jie Liu; Yue Xiao; Xikun Wu; Lichun Jiang; Shurong Yang; Zhiming Ding; Zhuo Fang; Haiqing Hua; Mark Stephen Kirby; Jianyong Shou
Journal:  BMC Genomics       Date:  2018-03-09       Impact factor: 3.969

4.  Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat.

Authors:  Yuanyuan Meng; Yong Liu; Ningning Fang; Yongmin Guo
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.889

5.  Ultrasonographic Evaluation of Fatty Pancreas in Serbian Patients with Non Alcoholic Fatty Liver Disease-A Cross Sectional Study.

Authors:  Tamara Milovanovic; Sanja Dragasevic; Milica Stojkovic Lalosevic; Sanja Zgradic; Biljana Milicic; Igor Dumic; Stefan Kmezic; Dusan Saponjski; Andrija Antic; Velimir Markovic; Dragan Popovic
Journal:  Medicina (Kaunas)       Date:  2019-10-17       Impact factor: 2.430

6.  Mice with Type 2 Diabetes Present Significant Alterations in Their Tissue Biomechanical Properties and Histological Features.

Authors:  Tânia B Cruz; Filomena A Carvalho; Paulo N Matafome; Raquel A Soares; Nuno C Santos; Rui D Travasso; Maria J Oliveira
Journal:  Biomedicines       Date:  2021-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.